Presenter Speech
Graham Glyn Parry (Analysts)
And welcome to the next session. So it's sticking with -- we've got a European pharma afternoon, in fact, pharma biotech afternoon. So we have with Genmab
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,043.00 DKK | -6.50% |
|
-5.50% | +0.79% |
| 01-19 | SHB: Overreaction in the Market to Genmab's Epkinly Study | FW |
| 01-19 | Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint | FW |
Published on 12/04/2025 at 04:06 pm GMT - Modified on 12/04/2025 at 07:20 pm GMT
Presenter Speech
Graham Glyn Parry (Analysts)
And welcome to the next session. So it's sticking with -- we've got a European pharma afternoon, in fact, pharma biotech afternoon. So we have with Genmab
Select your edition
All financial news and data tailored to specific country editions